Meeting
2023 ASCO Annual Meeting
Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).
Authors
Peter C. Thuss-Patience
Charité University Medicine Berlin, Department of Haematology, Oncology and Cancer Immunology, Campus Virchow-Klinikum, Berlin, Germany
Peter C. Thuss-Patience , Anica Högner , Eray Goekkurt , Michael Stahl , Albrecht Kretzschmar , Thorsten Oliver Goetze , Gertraud Stocker , Peter Reichardt , Frank Kullmann , Daniel Pink , Prisca Bartels , Armin Jarosch , Axel Hinke , Lisa Paschold , Alexander Stein , Mascha Binder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03966118
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4032)
DOI
10.1200/JCO.2023.41.16_suppl.4032
Abstract #
4032
Poster Bd #
353
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price
Poster
2020 ASCO Virtual Scientific Program
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
First Author: Sylvie Lorenzen
Poster
2019 ASCO Annual Meeting
RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).
First Author: Anica Högner
Poster
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
First Author: Charles S. Fuchs